1. Home
  2. BRT vs IKT Comparison

BRT vs IKT Comparison

Compare BRT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BRT Apartments Corp. (MD)

BRT

BRT Apartments Corp. (MD)

N/A

Current Price

$14.10

Market Cap

271.2M

Sector

Real Estate

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$2.46

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BRT
IKT
Founded
1972
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.2M
220.5M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
BRT
IKT
Price
$14.10
$2.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$19.75
$5.00
AVG Volume (30 Days)
33.3K
945.6K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
7.03%
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
$97,028,000.00
N/A
Revenue This Year
$3.82
N/A
Revenue Next Year
$5.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.46
N/A
52 Week Low
$13.18
$1.33
52 Week High
$16.69
$2.53

Technical Indicators

Market Signals
Indicator
BRT
IKT
Relative Strength Index (RSI) 36.65 68.09
Support Level $13.18 $1.63
Resistance Level $15.04 $2.53
Average True Range (ATR) 0.45 0.14
MACD -0.10 0.01
Stochastic Oscillator 19.04 92.68

Price Performance

Historical Comparison
BRT
IKT

About BRT BRT Apartments Corp. (MD)

BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: